The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
|Articles|June 25, 2007
NIOSH: 62 new drugs are potentially hazardous
The National Institute for Occupational Safety & Health (NIOSH) has proposed a new list of 62 medications that it thinks fit its criteria for hazardous drugs and a list of 88 products that don't fit those criteria.
Advertisement
The National Institute for Occupational Safety & Health (NIOSH) has proposed a new list of 62 medications that it thinks fit its criteria for hazardous drugs and a list of 88 products that don't fit those criteria. The lists are posted on its Web site at
Advertisement
Related to this article
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Community pharmacists offer accessible care, improve medication adherence, and build trust through education, vaccination support, and local health leadership.
Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.
Advertisement
Advertisement
Trending on Drug Topics
1
What Is HIV PrEP and Who Needs It Most?
2
Indirect Comparison Links Tirzepatide to Greater Weight Loss Than Semaglutide
3
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
4
Validating Fear Before Facts: A Framework for COVID-19 Hesitancy
5